Howard S. Hochster, MD

Howard S. Hochster, MD, reviews the potential solutions for the current chemotherapy drug shortages, and how this can be avoided in the future.

Co-editor-in-chief, Howard S. Hochster, MD, reviews the ongoing drug price negotiations and the effect it will have in the health care space.

Co-editor-in-Chief Howard S. Hochster, MD, writes about the past and present of the phase 2/3 PROSPECT trial.

Co-editor-in-Chief Howard S. Hochster, MD, discusses persistent obstacles to the effective use of biosimilars in clinical practice.

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

Co-editor-in-Chief Howard S. Hochster, MD, highlights the most exciting developments from the 2023 Gastrointestinal Cancer Symposium hosted by the American Society of Clinical Oncology (ASCO).

Co-editor-in-Chief Howard S. Hochster, MD, discusses disparities in access to health care between urban and rural patients with breast cancer, and how they might be addressed.

Co-editor-in-Chief Howard S. Hochster, MD, reviews the major clinical and scientific developments of 2022 in the oncology space.

Co-editor-in-Chief Howard S. Hochster, MD, highlights exciting clinical trials that may set future standards for adjuvant therapy selection in colon cancer.

Howard S. Hochster, MD, considers drug price negotiation in this month's Letter to the Readers.

Stacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.

In this month's Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, discusses oxaliplatin hypersensitivity reaction in gastrointestinal cancer.

In this month's Letter to the Readers, ONCOLOGy co-editor-in-chief Howard Hochster, MD, reviews the implications of legal disputes surrounding patents for CRISPR technology.

In this month’s Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, reviews results of the CIRCULATE-Japan clinical trial that were presented at the 2022 Gastrointestinal Cancers Symposium.

ONCOLOGY® co-editor-in-chief Howard S. Hochster, MD, reviews research on delays in oncology care as a result of the COVID-19 pandemic.

CancerNetwork®’s podcast hosted 2 experts to discuss the current state of biosimilar prescriptions and the need for change to improve the system overall.

In his "Letter to the Readers", co-editor-in-chief of the journal ONCOLOGY Howard S. Hochster, MD, reviews the utility of next-generation sequencing in pancreatic ductal adenocarcinoma.

In his "Letter to the Readers", co-editor-in-chief of the journal ONCOLOGY Howard S. Hochster, MD, reviews the development of mRNA technology, especially as it applies to vaccines against COVID-19.

Unprecedented efforts from researchers and pharmaceutical engineers have brought about safe, effective vaccines, in record development times; now the focus must be on a federally coordinated program to administer those injections in the most efficient manner possible.

Intense political pressure and questionable decisions have caused the once-vaunted reputation of the FDA to come under fire.

ONCOLOGY Editor in Chief Howard S. Hochster, MD stresses the need for properly designed, controlled and randomized trials during the time of COVID-19